COVID-19 & Solid Tumors: a 6-Week Webcast Series

COVID-19 & Solid Tumors: a 6-Week Webcast Series

On-Demand Webcast
COVID-19 & Solid Tumors: Module 1 – Lung Tumors Expert Round Table

Approved for 1 CME/CNE/CPE/AAPA Credit

Corey J. Langer, MD; Michael P. Angarone, DO; Marina Garassino, MD; Andrew R. Haas, MD, PhD; Roy S. Herbst, MD, PhD

Click HERE to watch

COVID-19 & SOLID TUMORS: MODULE 2 – LUNG TUMORS UPDATE 1

Approved for 0.25 CME/CNE/CPE/AAPA Credit

Corey J. Langer, MD; Marina Garassino, MD

Click HERE to watch

COVID-19 & Solid Tumors: Module 3 – Lung Tumors Update 2

Approved for 0.25 CME/CNE/CPE/AAPA Credit

Corey J. Langer, MD; Roy S. Herbst, MD, PhD

Click HERE to watch

COVID-19 & Solid Tumors: Module 4 – GI Tumors Expert Round Table

Approved for 1 CME/CNE/CPE/AAPA Credit

Axel Grothey, MD; Cathy Eng, MD, FACP, FASCO;Steven Pergam, MD, MPH; Alberto Sobrero, MD

Click HERE to watch

COVID-19 & Solid Tumors: Module 5 – GI Tumors Update 1

Approved for 0.25 CME/CNE/CPE/AAPA Credit

Axel Grothey, MD; Cathy Eng, MD, FACP, FASCO

Click HERE to watch

COVID-19 & Solid Tumors: Module 6 – GI Tumors Update 2

Approved for 0.25 CME/CNE/CPE/AAPA Credit

Axel Grothey, MD; Alberto Sobrero, MD

Click HERE to watch

Intended Learners

This activity is intended for clinicians who encounter patients with lung and GI malignancies, including medical, radiation, and surgical oncologists; and other HCPs, such as internists/hospitalists, infectious disease specialists, pulmonologists, critical care specialists, medical students, oncology nurses, nurse practitioners, physician assistants, and pharmacists working as part of the multidisciplinary oncology team during the COVID-19 pandemic.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Describe up-to-the-minute developments in the epidemiology, pathology, and current treatment approaches of/for COVID-19
  • Develop risk-mitigation strategies to limit patient and provider exposure to SARS-CoV-2 without compromising effective diagnostic and therapeutic management of cancer
  • Evaluate the interplay between solid tumors and COVID-19 in terms of susceptibility to SARS-CoV- 2 and, in case of infection, effects of severity of COVID-19 and tumor progression
  • Identify, mitigate, and manage current and prospective diagnostic, therapeutic, and monitoring challenges in oncology care due to the reallocation of health resources as a result of the COVID- 19 pandemic
Commercial Support

This program is supported through educational grants from Merck Sharp & Dohme Corp, and Pfizer, Inc.